ChemoCentryx, Inc. (CCXI)
| Previous close | 37.06 |
| Open | 37.54 |
| Bid | 35.42 x 1100 |
| Ask | 35.56 x 1800 |
| Day's range | 34.68 - 37.54 |
| 52-week range | 9.53 - 70.29 |
| Volume | |
| Avg. volume | 5,019,214 |
| Market cap | 2.462B |
| Beta (5Y monthly) | 1.83 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.74 |
| Earnings date | 28 Feb 2022 - 04 Mar 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 71.63 |
- Simply Wall St.
ChemoCentryx's (NASDAQ:CCXI) investors will be pleased with their incredible 382% return over the last five years
Long term investing can be life changing when you buy and hold the truly great businesses. While not every stock...
- Zacks
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
- GlobeNewswire
Positive Recommendation for Use of TAVNEOS™ (avacopan) in ANCA Vasculitis Adopted by European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP)
SAN CARLOS, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending marketing authorization for the Company’s TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, in combination with a rituximab or cyclophosphamide regimen, indicated for the treatment of adult patients with severe, active g
